Test Bank For Clayton’s Basic Pharmacology for Nurses 19th Edition B
8 8 8 8 8 8 8 8 8 8
y Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Complet
8 8 8 8 8 8 8 8 8
e
,Chapter 01: Drug Definitions, Standards, and Information Sources Willihnganz:
8 8 8 8 8 8 8 8 8
Clayton’s Basic Pharmacology for Nurses, 19th Edition
8 8 8 8 8 8
MULTIPLE8CHOICE
1. Which8name8identifies8a8drug8listed8by8the8US8Food8and8
Drug8Administration8(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS:8 C
The8official8name8is8the8 name8under8which8a8drug8is8listed8by
8the8FDA.8The8brand8name,8or8trademark,8is8the8name8given8t
o8a8drug8by8its8manufacturer.8The8nonproprietary,8or8generic,8
name8is8provided8by8the8United8States8Adopted8Names8Coun
cil.
DIF: Cognitive8Level:8Knowledge REF:8 p.89
OBJ:81NAT:8NCLEX8Client8Needs8Category:8Safe,8Effective8Care8
Environment8TOP:8 Nursing8Process8Step:8Assessment
CON:8
Patient8Education
2. Which8source8contains8information8specific8to8nutritional8supplements?
a. USP8Dictionary8of8USAN8&8International8Drug8Names
b. Natural8Medicines8Comprehensive8Database
c. United8States8Pharmacopoeia/National8Formulary8(USP8NF)
d. Drug8Interaction8Facts
ANS:8 C
United8States8Pharmacopoeia/National8Formulary8contains8information8specific8to8nutritional8
supplements.8USP8Dictionary8of8USAN8&8International8Drug8Names8is8a8compilation8of8drug8n
ames,8pronunciation8guide,8and8possible8future8FDA8approved8drugs;8it8does8not8include8nutriti
onal8supplements.8Natural8Medicines8Comprehensive8Database8contains
evidence-
based8information8on8herbal8medicines8and8herbal8combination8products;8it8does8not8include8inf
ormation8specific8to8nutritional8supplements.8Drug8Interaction8Facts8contains8comprehensive8i
nformation8on8drug8interaction8facts;8it8does8not8include8nutritional8supplements.
DIF: Cognitive8Level:8Knowledge REF:8 p.84
OBJ:838NAT:8 NCLEX8Client8Needs8Category:8Physiological8Integ
rity
TOP:8 Nursing8Process8Step:8Assessment CON:8 Nutrition8|8Patient8Education
3. Which8drug8reference8contains8drug8monographs8that8describe8all8drugs8in8a8therapeutic8class?
a. Drug8Facts8and8Comparisons
,Test8Bank8For8Clayton’s8Basic8Pharmacology8for8Nurses819th8Edition 3
b. Drug8Interaction8Facts
c. Handbook8on8Injectable8Drugs
d. Martindale—The8Complete8Drug8Reference
ANS:8 A
Drug8Facts8and8Comparisons8contains8drug8monographs8that8describe8all8drugs8in8a8th
erapeutic8class.8Monographs8are8formatted8as8tables8to8allow8comparison8of8similar8pro
ducts,8brand8names,8manufacturers,8cost8indices,8and8available8dosage8forms8Online8ve
rsion8is8available.
DIF: Cognitive8Level:8Knowledge REF:8 p.848Table81.2
OBJ:8 8 3 NAT:8 NCLEX8Client8Needs8Category:8Physiological8Integrity
TOP:8 Nursing8Process8Step:8Assessment CON:8 Safety8|8Patient8Education8|8Clinical8Judgment
4. Which8drug8reference8contains8monographs8about8virtually8every8single-
entity8drug8available8in8the8United8States8and8describes8therapeutic8uses8of8drugs,8including8ap
proved8and8unapproved8uses?
a. Martindale:8The8Complete8Drug8Reference
b. AHFS8Drug8Information
c. Drug8Reference
d. Drug8Facts8and8Comparisons
ANS:8 B
AHFS8Drug8Information8contains8monographs8about8virtually8every8single-
entity8drug8available8in8the8United8States8and8describes8therapeutic8uses8of8drugs,8including8appr
oved8and8unapproved8uses.
DIF: Cognitive8Level:8Knowledge REF:8 p.848Table81.2
OBJ:8 8 3 NAT:8 NCLEX8Client8Needs8Category:8Physiological8Integrity
TOP:8 Nursing8Process8Step:8Planning CON:8 Safety8|8Patient8Education8|8Clinical8Judgment
5. Which8online8drug8reference8makes8available8to8healthcare8providers8and8the8public8a8stand
ard,8comprehensive,8up-to-date8look8up8and8downloadable8resource8about8medicines?
a. American8Drug8Index
b. American8Hospital8Formulary
c. DailyMed
d. Drug8Reference
ANS:8 C
DailyMed8makes8available8to8healthcare8providers8and8the8public8a8standard,8comprehensive,8
up-to-
date8look8up8and8downloadable8resource8about8medicines.8The8American8Drug8Index8is8not8app
ropriate8for8patient8use.8The8American8Hospital8Formulary8is8not8appropriate8for8patient8use.8
The8drug8reference8is8not8appropriate8for8patient8use.
DIF: Cognitive8Level:8Knowledge REF:8 p.838|8p.84
OBJ:838NAT:8 NCLEX8Client8Needs8Category:8Physiological8Integ
rity
TOP:8 Nursing8Process8Step:8Implementation
CON:8 Safety8|8Patient8Education8|8Clinical8Judgment
6. Which8legislation8authorizes8the8FDA8to8determine8the8safety8of8a8drug8before8its8marketing?
a. Federal8Food,8Drug,8and8Cosmetic8Act8(1938)
b. Durham8Humphrey8Amendment8(1952)
, Test8Bank8For8Clayton’s8Basic8Pharmacology8for8Nurses819th8Edition 4
c. Controlled8Substances8Act8(1970)
d. Kefauver8Harris8Drug8Amendment8(1962)
ANS:8 A
The8Federal8Food,8Drug,8and8Cosmetic8Act8of819388authorized8the8FDA8to8determine8the8safet
y8of8all8drugs8before8marketing.8Later8amendments8and8acts8helped8tighten8FDA8control8and8en
sure8drug8safety.8The8Durham8Humphrey8Amendment8defines8the8kinds8of8drugs8that8cannot8be
8used8safely8without8medical8supervision8and8restricts8their8sale8to8prescription8by8a8licensed8pr
actitioner.8The8Controlled8Substances8Act8addresses8only8controlled8substances8and8their8catego
rization.8The8Kefauver8Harris8Drug8Amendment8ensures8drug8efficacy8and8greater8drug8safety.8
Drug8manufacturers8are8required8to8prove8to8the8FDA8the8effectiveness8of8their8products8before
8marketing8them.
DIF: Cognitive8Level:8Knowledge REF:8 p.858Table8l.3
OBJ:8 5
NAT:8NCLEX8Client8Needs8Category:8Physiological8Integrity8
TOP:8 Nursing8Process8Step:8Assessment
CON:8 Safety8|8Patient8Education8|8Evidence8|8Health8Care8Law
7. Which8classification8does8meperidine8(Demerol)8fall8under?
a. I
b. II
c. III
d. IV
ANS:8 B
Meperidine8(Demerol)8is8a8Schedule8II8drug;8it8has8a8high8potential8for8abuse8and8may8lead8to8se
vere8psychological8and8physical8dependence.8Schedule8I8drugs8have8high8potential8for8abuse8and
8no8recognized8medical8use.8Schedule8III8drugs8have8some8potential8for8abuse.8Use8may8lead8to8
low8to8moderate8physical8dependence8or8high8psychological8dependence.8Schedule8IV8drugs8ha
ve8low8potential8for8abuse.8Use8may8lead8to8limited8physical8or8psychological8dependence.
DIF: Cognitive8Level:8Knowledge REF:8 p.810
OBJ:828NAT:8 NCLEX8Client8Needs8Category:8Safe,8Effective8Car
e8Environment
TOP:8 Nursing8Process8Step:8Assessment CON:8 Patient8Education8|8Addiction8|8Pain
8. Which8action8would8the8FDA8take8to8expedite8drug8development8and8approval8for8an8outbreak8o
f8smallpox?
a. List8smallpox8as8a8health8orphan8disease.
b. Omit8the8preclinical8research8phase.
c. Extend8the8clinical8research8phase.
d. Fast8track8the8investigational8drug.
ANS:8 D
Once8the8Investigational8New8Drug8Application8has8been8approved,8the8drug8can8receive8high
est8priority8within8the8agency,8which8is8called8fast8tracking.8A8smallpox8outbreak8would8beco
me8a8priority8concern8in8the8world.8Orphan8diseases8are8not8researched8in8a8priority8manner.8Pr
eclinical8research8is8not8omitted.8Extending8any8phase8of8the8research8would8mean8a8longer8tim
e8to8develop8a8vaccine.8The8FDA8must8ensure8that8all8phases8of8the8preclinical8and8clinical8resea
rch8phase8have8been8completed8in8a8safe8manner.
DIF: Cognitive8Level:8Knowledge REF:8 8 p.87 OBJ:8 5
8 8 8 8 8 8 8 8 8 8
y Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Complet
8 8 8 8 8 8 8 8 8
e
,Chapter 01: Drug Definitions, Standards, and Information Sources Willihnganz:
8 8 8 8 8 8 8 8 8
Clayton’s Basic Pharmacology for Nurses, 19th Edition
8 8 8 8 8 8
MULTIPLE8CHOICE
1. Which8name8identifies8a8drug8listed8by8the8US8Food8and8
Drug8Administration8(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS:8 C
The8official8name8is8the8 name8under8which8a8drug8is8listed8by
8the8FDA.8The8brand8name,8or8trademark,8is8the8name8given8t
o8a8drug8by8its8manufacturer.8The8nonproprietary,8or8generic,8
name8is8provided8by8the8United8States8Adopted8Names8Coun
cil.
DIF: Cognitive8Level:8Knowledge REF:8 p.89
OBJ:81NAT:8NCLEX8Client8Needs8Category:8Safe,8Effective8Care8
Environment8TOP:8 Nursing8Process8Step:8Assessment
CON:8
Patient8Education
2. Which8source8contains8information8specific8to8nutritional8supplements?
a. USP8Dictionary8of8USAN8&8International8Drug8Names
b. Natural8Medicines8Comprehensive8Database
c. United8States8Pharmacopoeia/National8Formulary8(USP8NF)
d. Drug8Interaction8Facts
ANS:8 C
United8States8Pharmacopoeia/National8Formulary8contains8information8specific8to8nutritional8
supplements.8USP8Dictionary8of8USAN8&8International8Drug8Names8is8a8compilation8of8drug8n
ames,8pronunciation8guide,8and8possible8future8FDA8approved8drugs;8it8does8not8include8nutriti
onal8supplements.8Natural8Medicines8Comprehensive8Database8contains
evidence-
based8information8on8herbal8medicines8and8herbal8combination8products;8it8does8not8include8inf
ormation8specific8to8nutritional8supplements.8Drug8Interaction8Facts8contains8comprehensive8i
nformation8on8drug8interaction8facts;8it8does8not8include8nutritional8supplements.
DIF: Cognitive8Level:8Knowledge REF:8 p.84
OBJ:838NAT:8 NCLEX8Client8Needs8Category:8Physiological8Integ
rity
TOP:8 Nursing8Process8Step:8Assessment CON:8 Nutrition8|8Patient8Education
3. Which8drug8reference8contains8drug8monographs8that8describe8all8drugs8in8a8therapeutic8class?
a. Drug8Facts8and8Comparisons
,Test8Bank8For8Clayton’s8Basic8Pharmacology8for8Nurses819th8Edition 3
b. Drug8Interaction8Facts
c. Handbook8on8Injectable8Drugs
d. Martindale—The8Complete8Drug8Reference
ANS:8 A
Drug8Facts8and8Comparisons8contains8drug8monographs8that8describe8all8drugs8in8a8th
erapeutic8class.8Monographs8are8formatted8as8tables8to8allow8comparison8of8similar8pro
ducts,8brand8names,8manufacturers,8cost8indices,8and8available8dosage8forms8Online8ve
rsion8is8available.
DIF: Cognitive8Level:8Knowledge REF:8 p.848Table81.2
OBJ:8 8 3 NAT:8 NCLEX8Client8Needs8Category:8Physiological8Integrity
TOP:8 Nursing8Process8Step:8Assessment CON:8 Safety8|8Patient8Education8|8Clinical8Judgment
4. Which8drug8reference8contains8monographs8about8virtually8every8single-
entity8drug8available8in8the8United8States8and8describes8therapeutic8uses8of8drugs,8including8ap
proved8and8unapproved8uses?
a. Martindale:8The8Complete8Drug8Reference
b. AHFS8Drug8Information
c. Drug8Reference
d. Drug8Facts8and8Comparisons
ANS:8 B
AHFS8Drug8Information8contains8monographs8about8virtually8every8single-
entity8drug8available8in8the8United8States8and8describes8therapeutic8uses8of8drugs,8including8appr
oved8and8unapproved8uses.
DIF: Cognitive8Level:8Knowledge REF:8 p.848Table81.2
OBJ:8 8 3 NAT:8 NCLEX8Client8Needs8Category:8Physiological8Integrity
TOP:8 Nursing8Process8Step:8Planning CON:8 Safety8|8Patient8Education8|8Clinical8Judgment
5. Which8online8drug8reference8makes8available8to8healthcare8providers8and8the8public8a8stand
ard,8comprehensive,8up-to-date8look8up8and8downloadable8resource8about8medicines?
a. American8Drug8Index
b. American8Hospital8Formulary
c. DailyMed
d. Drug8Reference
ANS:8 C
DailyMed8makes8available8to8healthcare8providers8and8the8public8a8standard,8comprehensive,8
up-to-
date8look8up8and8downloadable8resource8about8medicines.8The8American8Drug8Index8is8not8app
ropriate8for8patient8use.8The8American8Hospital8Formulary8is8not8appropriate8for8patient8use.8
The8drug8reference8is8not8appropriate8for8patient8use.
DIF: Cognitive8Level:8Knowledge REF:8 p.838|8p.84
OBJ:838NAT:8 NCLEX8Client8Needs8Category:8Physiological8Integ
rity
TOP:8 Nursing8Process8Step:8Implementation
CON:8 Safety8|8Patient8Education8|8Clinical8Judgment
6. Which8legislation8authorizes8the8FDA8to8determine8the8safety8of8a8drug8before8its8marketing?
a. Federal8Food,8Drug,8and8Cosmetic8Act8(1938)
b. Durham8Humphrey8Amendment8(1952)
, Test8Bank8For8Clayton’s8Basic8Pharmacology8for8Nurses819th8Edition 4
c. Controlled8Substances8Act8(1970)
d. Kefauver8Harris8Drug8Amendment8(1962)
ANS:8 A
The8Federal8Food,8Drug,8and8Cosmetic8Act8of819388authorized8the8FDA8to8determine8the8safet
y8of8all8drugs8before8marketing.8Later8amendments8and8acts8helped8tighten8FDA8control8and8en
sure8drug8safety.8The8Durham8Humphrey8Amendment8defines8the8kinds8of8drugs8that8cannot8be
8used8safely8without8medical8supervision8and8restricts8their8sale8to8prescription8by8a8licensed8pr
actitioner.8The8Controlled8Substances8Act8addresses8only8controlled8substances8and8their8catego
rization.8The8Kefauver8Harris8Drug8Amendment8ensures8drug8efficacy8and8greater8drug8safety.8
Drug8manufacturers8are8required8to8prove8to8the8FDA8the8effectiveness8of8their8products8before
8marketing8them.
DIF: Cognitive8Level:8Knowledge REF:8 p.858Table8l.3
OBJ:8 5
NAT:8NCLEX8Client8Needs8Category:8Physiological8Integrity8
TOP:8 Nursing8Process8Step:8Assessment
CON:8 Safety8|8Patient8Education8|8Evidence8|8Health8Care8Law
7. Which8classification8does8meperidine8(Demerol)8fall8under?
a. I
b. II
c. III
d. IV
ANS:8 B
Meperidine8(Demerol)8is8a8Schedule8II8drug;8it8has8a8high8potential8for8abuse8and8may8lead8to8se
vere8psychological8and8physical8dependence.8Schedule8I8drugs8have8high8potential8for8abuse8and
8no8recognized8medical8use.8Schedule8III8drugs8have8some8potential8for8abuse.8Use8may8lead8to8
low8to8moderate8physical8dependence8or8high8psychological8dependence.8Schedule8IV8drugs8ha
ve8low8potential8for8abuse.8Use8may8lead8to8limited8physical8or8psychological8dependence.
DIF: Cognitive8Level:8Knowledge REF:8 p.810
OBJ:828NAT:8 NCLEX8Client8Needs8Category:8Safe,8Effective8Car
e8Environment
TOP:8 Nursing8Process8Step:8Assessment CON:8 Patient8Education8|8Addiction8|8Pain
8. Which8action8would8the8FDA8take8to8expedite8drug8development8and8approval8for8an8outbreak8o
f8smallpox?
a. List8smallpox8as8a8health8orphan8disease.
b. Omit8the8preclinical8research8phase.
c. Extend8the8clinical8research8phase.
d. Fast8track8the8investigational8drug.
ANS:8 D
Once8the8Investigational8New8Drug8Application8has8been8approved,8the8drug8can8receive8high
est8priority8within8the8agency,8which8is8called8fast8tracking.8A8smallpox8outbreak8would8beco
me8a8priority8concern8in8the8world.8Orphan8diseases8are8not8researched8in8a8priority8manner.8Pr
eclinical8research8is8not8omitted.8Extending8any8phase8of8the8research8would8mean8a8longer8tim
e8to8develop8a8vaccine.8The8FDA8must8ensure8that8all8phases8of8the8preclinical8and8clinical8resea
rch8phase8have8been8completed8in8a8safe8manner.
DIF: Cognitive8Level:8Knowledge REF:8 8 p.87 OBJ:8 5
